Neuronal Paraneoplastic Autoantibodies Profile Advanced Test
Comprehensive Detection of Cancer-Related Neurological Disorders
The Neuronal Paraneoplastic Autoantibodies Profile Advanced Test represents a cutting-edge diagnostic approach for identifying paraneoplastic neurological syndromes (PNS). These complex conditions occur when the body’s immune system mistakenly targets nervous system tissues while fighting an underlying cancer. Our advanced testing methodology provides clinicians with critical information to detect these rare but serious disorders early, potentially revealing hidden malignancies before they become clinically apparent through conventional screening methods.
What This Advanced Test Measures
This comprehensive profile utilizes sophisticated immunoblot technology to detect nine specific autoantibodies associated with paraneoplastic neurological syndromes:
- Amphiphysin – Associated with stiff-person syndrome and breast cancer
- CV2 (CRMP5) – Linked to various neurological symptoms and small cell lung cancer
- PNMA2 (Ma2/Ta) – Connected to limbic encephalitis and testicular cancer
- ANNA-1/Hu – Related to encephalomyelitis and small cell lung cancer
- ANNA-2/Ri – Associated with opsoclonus-myoclonus and breast cancer
- PCA-1/Yo – Linked to cerebellar degeneration and ovarian/breast cancer
- SOX1 – Marker for Lambert-Eaton myasthenic syndrome and small cell lung cancer
- Titin – Associated with myasthenia gravis and thymoma
- Recoverin – Connected to cancer-associated retinopathy
Who Should Consider This Advanced Testing
This comprehensive autoantibody profile is particularly valuable for patients experiencing unexplained neurological symptoms that may indicate an underlying paraneoplastic syndrome. Consider this test if you or your patient presents with:
- Progressive neurological symptoms without clear explanation
- Rapidly developing cognitive impairment or memory loss
- Unexplained muscle weakness, stiffness, or coordination problems
- Involuntary muscle movements or tremors
- Vision changes or eye movement abnormalities
- Sensory disturbances or numbness
- Seizures of recent onset
- Previous cancer diagnosis with new neurological symptoms
Significant Benefits of Advanced Paraneoplastic Testing
Early detection through our Neuronal Paraneoplastic Autoantibodies Profile Advanced Test offers multiple clinical advantages:
- Early Cancer Detection – Identifies hidden malignancies before conventional methods
- Accurate Diagnosis – Provides definitive answers for complex neurological cases
- Treatment Guidance – Helps oncologists develop targeted treatment strategies
- Prognostic Information – Assists in predicting disease course and outcomes
- Comprehensive Coverage – Tests for nine critical autoantibodies in a single profile
- Rapid Results – Same-day reporting when samples are collected properly
Understanding Your Test Results
Your Neuronal Paraneoplastic Autoantibodies Profile Advanced Test results will provide valuable insights into potential underlying conditions:
- Positive Results – Detection of specific autoantibodies indicates a high probability of paraneoplastic neurological syndrome and may suggest associated cancer types
- Negative Results – Absence of detected autoantibodies reduces likelihood of paraneoplastic syndrome but doesn’t completely rule out the possibility
- Pattern Interpretation – Different autoantibody patterns correlate with specific neurological syndromes and cancer types
- Clinical Correlation – Results should always be interpreted alongside clinical symptoms and other diagnostic findings
- Follow-up Testing – Positive results typically warrant comprehensive cancer screening and neurological evaluation
Test Details and Pricing
| Test Component | Details | Price (USD) |
|---|---|---|
| Test Name | Neuronal Paraneoplastic Autoantibodies Profile Advanced Test | – |
| Discount Price | Limited Time Special Offer | $376 |
| Regular Price | Standard Testing Fee | $500 |
| Sample Type | 2 mL (1 mL min.) serum from 1 SST | – |
| Turnaround Time | Same day (Sample Mon through Sat by 9 AM) | – |
| Methodology | Advanced Immunoblot Technology | – |
| Preparation | No special preparation required | – |
Nationwide Testing Availability
GGC DNA maintains comprehensive testing facilities across the United States, with convenient locations in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our advanced laboratory network ensures consistent, high-quality testing standards regardless of your location.
Take Action for Your Neurological Health
Don’t let unexplained neurological symptoms go undiagnosed. Our Neuronal Paraneoplastic Autoantibodies Profile Advanced Test provides the comprehensive analysis needed to detect potential cancer-related neurological disorders. Early detection can significantly impact treatment outcomes and quality of life.
Ready to schedule your test? Contact our dedicated healthcare team today:
Phone: +1(267) 388-9828
Available for consultation and appointment scheduling
Our experienced medical professionals will guide you through the testing process, answer your questions, and help you understand the importance of comprehensive paraneoplastic screening for optimal neurological health management.
